KLK5: A Potential Drug Target and Biomarker (G25818)

Target Name: KLK5

NCBI ID: G25818

KLK5

KLK5: A Potential Drug Target and Biomarker

Kallikrein-like protein 2 (KLK5) is a gene that encodes a protein known for its role in various physiological processes in the body. The protein is involved in the regulation of blood clotting, which is a critical function that helps maintain blood flow and oxygenation to the body's tissues. Unfortunately, abnormal blood coagulation can lead to thrombosis and increase the risk of cardiovascular and cerebrovascular diseases. Therefore, KLK5 has high value in drug research and clinical applications.

KLK5 is a transmembrane protein whose encoding gene is a DNA segment in the human genome. The expression product of the KLK5 gene is a protein with a molecular weight of 21.1 kDa, which has a single polypeptide chain consisting of 124 amino acids. The KLK5 protein is produced by intracellular gene transcription and translation processes. In cells, KLK5 protein is mainly located on the cytoplasmic membrane and expressed on the endoplasmic reticulum membrane. It is a protein that functions on the cell membrane.

The role of KLK5 in physiology is mainly to promote blood coagulation and hemostatic processes. During blood coagulation, the KLK5 protein interacts with fibrinogen and platelet membrane phospholipids, helping to convert fibrinogen into fibrin, thereby forming thrombus. During the process of hemostasis, KLK5 protein can inhibit the growth and proliferation of vascular endothelial cells, helping to stop bleeding and repair damaged blood vessels.

Abnormal expression of KLK5 is closely related to the occurrence and development of various diseases. Studies have found that variations in the KLK5 gene are closely related to the occurrence and development of various cancers (such as lung cancer, liver cancer, breast cancer, etc.). In addition, the expression level of KLK5 gene is also closely related to the risk of cardiovascular diseases (such as hypertension, coronary heart disease, arrhythmia, etc.).

In drug research, KLK5 is considered a potential drug target. Currently, a variety of drugs that inhibit KLK5 expression have been approved for clinical use, such as the antiplatelet drug Clopidogrel and the anticoagulant drug Heparin. These drugs exert their antiplatelet and anticoagulant effects by inhibiting the synthesis of the KLK5 protein.

In addition, KLK5 has also been used as a biomarker to detect disease progression and treatment efficacy. For example, by measuring the levels of the KLK5 protein in the blood, it is possible to evaluate the effectiveness of treatment in cancer patients and predict the risk of disease progression.

As a transmembrane protein, KLK5 has high value in drug research and clinical applications. With the deepening of research, the role of KLK5 protein in drug development and disease treatment will be more explored and utilized.

Protein Name: Kallikrein Related Peptidase 5

Functions: May be involved in desquamation

The "KLK5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KLK5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets